This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases | MicrobiomeTrials
← Back to trials NCT07389499
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases Recruiting EARLY_PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2027-08Est. Completion: 2028-06-30
Enrollment target: 30 participantsLocations Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China Other microbiome trials you might be interested in Immunoglobulin A (IgA) Nephropathy
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of …
Miami, United States Est. completion Sep 2028
Primary Immunoglobulin A Nephropathy (IgAN)
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetic…
Madera, United States Est. completion Jun 28, 2030